A Phase 3 interventional study of Aliskiren/Amlodipine 150/2.5 mg and Aliskiren/amlodipine 150/5 mg in Essential Hypertension, sponsored by Novartis. Completed at 11 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-06-13.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2010, is one of 15 in phase 3, and was the 17th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 16 · Phase 4 5
First in 2005; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,342 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 506 across the 25 interventional studies, 20,984 across the 2 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Essential Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and \< 110 mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.
Drug: Aliskiren 150 mg · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.
Drug: Amlodipine 2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.
Drug: Amlodipine 2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period.
Drug: Aliskiren/Amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/5 mg
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.
Drug: Aliskiren/amlodipine 150/5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg
Aliskiren/amlodipine 150/2.5 mg tablet
Aliskiren/amlodipine 150/5 mg tablet
Aliskiren 150 mg tablet
Amlodipine 2.5 mg capsule
Aliskiren placebo tablet
Amlodipine placebo capsule
Aliskiren/amlodipine 150/2.5 mg placebo tablet
Aliskiren/amlodipine 150/5 mg placebo tablet
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)
Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)
Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.
Time frame: Baseline, Week 8
Percentage of Participants Achieving Blood Pressure Control at Endpoint
Blood pressure control is defined as having as a msDBP \< 90 mmHg and a msSBP \< 140 mmHg.
Time frame: 8 weeks
Percentage of Participants Achieving a Successful Response Rate
The response rate was defined as percentage of participants who achieved msDBP \< 90 mmHg or its reduction ≥ 10 mmHg from baseline to endpoint.
Time frame: 8 weeks
Number of Participants With Adverse Events, Serious Adverse Events and Death
Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.
Time frame: 8 weeks
| Milestone | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Started | 1342 | 0 | 0 | 0 | 0 | 0 |
| Completed | 944 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 398 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 29 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal laboratory value(s) | 25 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 308 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 28 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation(s) | 8 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Started | 153 | 157 | 158 | 158 | 159 | 159 |
| Completed | 120 | 142 | 143 | 153 | 155 | 154 |
| Not completed | 33 | 15 | 15 | 5 | 4 | 5 |
| Withdrew: Adverse event | 12 | 4 | 3 | 2 | 2 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 20 | 6 | 7 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 | 4 | 0 | 1 | 1 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation(s) | 0 | 1 | 1 | 2 | 1 | 1 |
Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.
| mm Hg | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8) | -5.21 ± 0.69 | -7.49 ± 0.68 | -9.46 ± 0.68 | -11.90 ± 0.68 | -12.40 ± 0.68 | -16.43 ± 0.68 |
Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.
| mm Hg | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8) | -4.57 ± 0.97 | -10.63 ± 0.96 | -13.16 ± 0.96 | -17.98 ± 0.96 | -18.15 ± 0.96 | -25.49 ± 0.96 |
Blood pressure control is defined as having as a msDBP \< 90 mmHg and a msSBP \< 140 mmHg.
| percentage of participants | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Blood Pressure Control at Endpoint | 16.3 | 25.5 | 32.9 | 50.0 | 45.9 | 69.2 |
The response rate was defined as percentage of participants who achieved msDBP \< 90 mmHg or its reduction ≥ 10 mmHg from baseline to endpoint.
| percentage of participants | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a Successful Response Rate | 34.6 | 46.5 | 50.6 | 70.3 | 65.4 | 86.2 |
Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.
| Participants | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|---|---|---|---|
| Adverse Events | 62 | 57 | 50 | 49 | 57 | 59 |
| Serious Adverse Events | 0 | 0 | 2 | 1 | 0 | 1 |
| Death | 0 | 0 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double Blind) | — | 0/153 (0%) | 21/153 (13.7%) |
| Aliskiren 150 mg | — | 0/157 (0%) | 21/157 (13.4%) |
| Amlodipine 2.5 mg | — | 2/158 (1.3%) | 17/158 (10.8%) |
| Amlodipine 5 mg | — | 1/158 (0.6%) | 21/158 (13.3%) |
| Aliskiren/Amlodipine 150/2.5 mg | — | 0/159 (0%) | 17/159 (10.7%) |
| Aliskiren/Amlodipine 150/5 mg | — | 1/159 (0.6%) | 19/159 (11.9%) |
| Placebo (Single-Blind run-in Period) | — | 4/1,342 (0.3%) | 136/1,342 (10.1%) |
| Event | Placebo (Double Blind) | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg | Placebo (Single-Blind run-in Period) |
|---|---|---|---|---|---|---|---|
| Gastric ulcerGastrointestinal disorders | 0/153 | 0/157 | 1/158 | 0/158 | 0/159 | 0/159 | 0/1342 |
| Herpes zoster oticusInfections and infestations | 0/153 | 0/157 | 0/158 | 1/158 | 0/159 | 0/159 | 0/1342 |
| PneumoniaInfections and infestations | 0/153 | 0/157 | 1/158 | 0/158 | 0/159 | 0/159 | 0/1342 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/153 | 0/157 | 0/158 | 0/158 | 0/159 | 1/159 | 0/1342 |
| Hypertensive encephalopathyNervous system disorders | 0/153 | 0/157 | 0/158 | 0/158 | 0/159 | 0/159 | 1/1342 |
| Putamen haemorrhageNervous system disorders | 0/153 | 0/157 | 0/158 | 0/158 | 0/159 | 0/159 | 1/1342 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/153 | 0/157 | 0/158 | 0/158 | 0/159 | 0/159 | 1/1342 |
| Hypertensive crisisVascular disorders | 0/153 | 0/157 | 0/158 | 0/158 | 0/159 | 0/159 | 1/1342 |
| Event | Placebo (Double Blind) | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg | Placebo (Single-Blind run-in Period) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/153 | 17/157 | 14/158 | 19/158 | 16/159 | 16/159 | 81/1342 |
| HeadacheNervous system disorders | 12/153 | 5/157 | 3/158 | 2/158 | 1/159 | 3/159 | 59/1342 |
| Age Continuous(years) | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.6 ± 8.35 | 55.0 ± 9.96 | 54.8 ± 10.25 | 55.8 ± 10.05 | 54.6 ± 11.11 | 55.5 ± 9.86 | 55.1 ± 9.96 |
| Age, Customized(participants) | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg | Total |
|---|---|---|---|---|---|---|---|
| < 65 years | 128 | 131 | 129 | 126 | 125 | 127 | 766 |
| >=65 years | 25 | 26 | 29 | 32 | 34 | 32 | 178 |
| Sex: Female, Male(Participants) | Placebo | Aliskiren 150 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/2.5 mg | Aliskiren/Amlodipine 150/5 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 45 | 39 | 45 | 51 | 51 | 57 | 288 |
| Male | 108 | 118 | 113 | 107 | 108 | 102 | 656 |
The record gives a start of Oct 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.